Related Experiment Video
Updated: Jul 20, 2026
Modeling Colitis-Associated Cancer with Azoxymethane AOM and Dextran Sulfate Sodium DSS
Published on: September 11, 2012
Advances in the study of disulfidptosis in digestive tract tumors
Yue Chen1, Dachuan Zhang2, Haonan Yang3
1Department of Oncology, The Third Affiliated Hospital of Soochow University, 185 Juqian Street, Changzhou, 213003, Jiangsu Province, China.
Abstract:
Disulfidptosis, a recently identified cell death mechanism, plays a pivotal role in the development, progression, and treatment of digestive tract tumors, including gastric cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, cholangiocarcinoma, and neuroendocrine tumors, which have high global incidence and mortality rates. Analyzing the expression of disulfidptosis-related gene expression within the tumor microenvironment enhances our understanding of tumor biology and facilitates novel diagnostic and therapeutic strategies. Research on immune infiltration and checkpoints can identify therapeutic targets linked to disulfidptosis, thereby improving immunotherapy efficacy. Targeting genes such as SLC7A11, which are essential for maintaining glutathione levels and regulating oxidative stress, may overcome chemoresistance and enhance existing treatments. Disulfidptosis could complement current therapies as it induces cytoskeletal collapse and selective tumor cell death, especially in chemoresistant cancers. Additionally, genes like SLC7A11, RPN1, and NCKAP1 in gastric cancer correlate with poor prognosis, highlighting their potential as prognostic biomarkers. Personalized medicine approaches utilizing disulfidptosis-related biomarkers could identify patients who would benefit from therapies targeting oxidative stress regulation, leading to more precise treatments and improved outcomes. This review summarizes disulfidptosis mechanisms, advancements in digestive cancers, and the potential of related genes for prognosis, immune response evaluation, and targeted therapies, providing novel perspectives for diagnosis and personalized treatment.
Insights
Disulfidptosis, a novel cell death pathway, is crucial in digestive cancers. Targeting related genes like SLC7A11 offers new strategies for diagnosis, prognosis, and overcoming chemoresistance in personalized medicine.
Area of Science:
- Cell Biology
- Oncology
- Molecular Medicine
Background:
- Disulfidptosis is a newly identified cell death mechanism with significant implications in digestive tract tumors.
- Digestive cancers, including gastric, liver, esophageal, colorectal, pancreatic, cholangiocarcinoma, and neuroendocrine tumors, exhibit high global incidence and mortality.
- Understanding disulfidptosis is key to advancing tumor biology insights and developing novel therapeutic strategies.
Purpose of the Study:
- To review the mechanisms of disulfidptosis and its role in digestive cancers.
- To explore the potential of disulfidptosis-related genes as diagnostic and prognostic biomarkers.
- To highlight the therapeutic potential of targeting disulfidptosis for improved cancer treatment and immunotherapy.
Main Methods:
- Literature review of disulfidptosis mechanisms and its involvement in various digestive cancers.
- Analysis of gene expression data related to disulfidptosis, including SLC7A11, RPN1, and NCKAP1.
- Examination of research on immune infiltration and checkpoints in relation to disulfidptosis.
Main Results:
- Disulfidptosis influences tumor development, progression, and treatment response in digestive cancers.
- Expression of genes like SLC7A11, RPN1, and NCKAP1 correlates with prognosis in gastric cancer.
- Targeting SLC7A11 may enhance treatment efficacy and overcome chemoresistance by regulating oxidative stress.
Conclusions:
- Disulfidptosis-related gene expression analysis aids in understanding tumor biology and developing diagnostic/therapeutic strategies.
- Disulfidptosis offers a complementary approach to current therapies, inducing selective tumor cell death, particularly in chemoresistant cancers.
- Personalized medicine utilizing disulfidptosis biomarkers can optimize treatment strategies for digestive cancers, improving patient outcomes.
